Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

80
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
80
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

21
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
21
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

984
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
984
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

26
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
26
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

655
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
655

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bacteriophage Therapy Against <i>Shigella</i> spp.: A Precision Antimicrobial Strategy.

Antibiotics (Basel, Switzerland)·2026
Same author

Liver and spleen stiffness as assessed by vibration-controlled transient elastography for diagnosing clinically significant portal hypertension in comparison with other elastography-based techniques in adults with chronic liver disease.

The Cochrane database of systematic reviews·2026
Same author

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.

Acta clinica Croatica·2025
Same author

GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease.

The Cochrane database of systematic reviews·2024
Same author

Correlation of the severity of the clinical presentation of SARS-CoV-2 pneumonia with respiratory function parameters in the post-COVID period.

Journal of infection in developing countries·2024
Same author

The Influence of Hemochromatosis Gene <i>(HFE)</i> Mutations on SARS-CoV-2 Susceptibility and COVID-19 Severity

Balkan medical journal·2023

Related Experiment Video

Updated: Apr 27, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

[Hepatitis C: who should be treated?].

Davor Stimac, Nikola Bradarić, Sandra Milić

    Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
    |July 3, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Hepatitis C therapy is recommended for patients with acute infection, elevated ALT, or advanced fibrosis. Treatment is also advised for specific patient groups, including those with co-infections or cirrhosis, but contraindicated in others.

    More Related Videos

    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    23.7K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    9.4K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.2K
    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    23.7K
    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
    10:28

    A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

    Published on: June 26, 2020

    9.4K

    Area of Science:

    • Hepatology
    • Virology
    • Internal Medicine

    Background:

    • Hepatitis C virus (HCV) infection poses significant global health challenges.
    • Treatment decisions for HCV require careful consideration of patient-specific factors and disease stage.

    Purpose of the Study:

    • To delineate the recommended and contraindicated patient populations for antiviral therapy in Hepatitis C.
    • To provide guidance on managing HCV in complex cases, including co-infections and specific comorbidities.

    Main Methods:

    • Review of clinical guidelines and evidence for Hepatitis C treatment recommendations.
    • Analysis of patient subgroups based on disease activity (ALT levels), fibrosis stage (METAVIR score), treatment history, and comorbidities.

    Main Results:

    • Strong recommendations for therapy in acute infection, elevated ALT, F ≥ 2 METAVIR score, nonresponders/relapsers to triple therapy, compensated cirrhosis, and hemodialysis patients.
    • Treatment is feasible for HBV/HIV co-infection, severe extrahepatic manifestations, liver transplant recipients, and post-abstinence drug/alcohol users.
    • Contraindications include fulminant hepatitis, persistent normal ALT without fibrosis, kidney transplant recipients, and pregnant women.

    Conclusions:

    • Antiviral therapy for Hepatitis C is highly individualized, with clear indications and contraindications.
    • Careful patient selection ensures optimal outcomes and avoids potential adverse events.